An Innovative Turning Point in Technology A research team at Stanford Medicine has successfully utilized mRNA technology to generate CAR-T cells directly within a patient's body. Traditional CAR-T therapy involves a complex and costly process of extracting a patient's T-cells, genetically modifying them in a laboratory, and then re-infusing them. This new study involved directly injecting mRNA to induce the patient's T-cells to express Chimeric Antigen Receptors (CARs) that recognize and attack cancer cells in vivo. Experiments in mice demonstrated effective elimination of blood cancer cells, suggesting the potential to significantly reduce treatment duration and cost. Improving Treatment Accessibility Currently, CAR-T therapy costs hundreds of millions of Korean Won per patient and requires specialized cell manufacturing facilities, severely limiting its accessibility. Globally, only about 20,000 patients annually can receive CAR-T treatment. The mRNA-based approach is a game-changer that can overcome these limitations. By eliminating the process of extracting and re-infusing patient cells, treatment time is shortened from weeks to days. Furthermore, like mass-producible mRNA vaccines, this method can significantly reduce costs. This opens the door for advanced cancer immunotherapy to be accessible even in low-income countries or regions with limited medical infrastructure. Future Clinical Prospects and Challenges Based on their success in mouse models, the research team aims to enter human clinical trials by 2026. However, there are challenges to overcome. These include improving the in-vivo delivery efficiency of mRNA, regulating immune responses, and verifying efficacy against solid tumors. Precision is particularly crucial to ensure that mRNA specifically targets T-cells and that CARs are not expressed in other cell types. The research team is enhancing T-cell specific delivery by improving lipid nanoparticle (LNP) technology, and accumulating clinical data across various cancer types will be key to future commercialization.